SCHEMBL2652340

SCHEMBL2652340

O=Cc1ccc2c(c1)ncn2-c1cccc(COCc2nccs2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 8/20 0.47
HPGD P15428 7/20 0.36
ALDH1A1 P00352 4/20 0.36
RAB9A P51151 3/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPT P10636 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
NPC1 O15118 2/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
GAA P10253 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2652890 0.88 GABRA1 (0.37) FGFR1HPGDALDH1A1RAB9AKDM4E
SCHEMBL2652227 0.84 PRKCI (0.40) FGFR1HPGDALDH1A1RAB9AKDM4E
SCHEMBL2652591 0.84 FGFR1 (0.39) FGFR1HPGDALDH1A1RAB9AKDM4E
SCHEMBL2977332 0.84 KIT (0.39) FGFR1HPGDALDH1A1RAB9AKDM4E
SCHEMBL2979088 0.83 FGFR1 (0.49) FGFR1HPGDALDH1A1RAB9AKDM4E
SCHEMBL2654799 0.82 FGFR1 (0.51) FGFR1ALDH1A1RAB9AKDM4EMAPT
SCHEMBL2651677 0.81 HPGD (0.47) FGFR1HPGDALDH1A1RAB9ATDP1
SCHEMBL2653350 0.81 FGFR1 (0.47) FGFR1HPGDALDH1A1RAB9AKDM4E
SCHEMBL2976344 0.80 NPC1 (0.42) FGFR1HPGDALDH1A1RAB9AKDM4E
SCHEMBL2969668 0.80 FGFR1 (0.46) FGFR1HPGDALDH1A1KMT2AGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US disclosed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US disclosed
EP-1874758-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2008-01-09 EP disclosed
WO-2006111516-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex GABRB2, GABRB1, GABRB3 FGFR1 4324/4885HPGD 1855/4885ALDH1A1 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.